Fig. 4From: Adjuvant trastuzumab duration trials in HER2 positive breast cancer – what results would be practice-changing? Persephone investigator questionnaire prior to primary endpoint resultsAcceptable 4-year DFS with 6-months trastuzumab to avoid hypothetical increased levels of cardiotoxicityBack to article page